The effect of liver disease on lactate normalization in severe sepsis and septic shock: a cohort study

Sarah A. Sterling, Michael A. Puskarich, Alan E. Jones
Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS, USA

Objective To describe the effect of liver disease (LD) on lactate clearance during early sepsis resuscitation.

Methods This is a multicenter randomized clinical trial. An initial lactate >2 mmol/L and subsequent serum lactate measurement within 6 hours were required for inclusion. LD was categorized by two methods: 1) past medical history (PMH) categorized as no LD, mild LD (no Child’s score criteria, but PMH of hepatitis B/C), cirrhosis; and 2) measurable liver dysfunction determined by the liver component of the sequential organ failure assessment (L-SOFA) score as no dysfunction (L-SOFA score 0), mild dysfunction (score 1), moderate-severe dysfunction (score 2 to 4). Primary outcome was the rate of lactate normalization.

Results One hundred eighty-seven patients were included. When categorized by PMH, 169 patients had no LD, 6 mild LD, and 12 cirrhosis. 63/169 (37%) of patients with no LD achieved lactate normalization, compared to 4/6 (67%) with mild LD, and 1/12 (8%) with cirrhosis (P<0.03). Categorized by L-SOFA score, 59/124 (47%) patients with L-SOFA 0 achieved lactate normalization, compared to 6/31 (19%) with L-SOFA 1, and 3/32 (9%) with L-SOFA 2–4 (P<0.01). Relative lactate clearance [(initial lactate–subsequent lactate)/initial lactate] was lower in patients with more advanced LD by PMH (37.7 vs. 40.4 vs. 21.8, P=0.07), and lower with increasing L-SOFA score (42.0 vs. 30.1 vs. 23.4, P=0.01).

Conclusion Liver dysfunction was significantly associated with impaired lactate clearance and normalization during the early resuscitation of sepsis.

Keywords Lactic acid; Liver diseases; Cirrhosis; Sepsis; Septic shock

What is already known
Although research has shown that the liver is the primary organ responsible for lactate clearance and that lactate clearance and normalization are associated with improved outcomes in severe sepsis and septic shock, to our knowledge, there has been no examination of the impact of liver dysfunction on lactate clearance and normalization in early resuscitations in sepsis.

What is new in the current study
This study evaluates the effect of liver disease on lactate clearance and normalization during early resuscitations in severe sepsis and septic shock. Our results indicate that liver dysfunction does impact lactate clearance and normalization, which could impact clinicians performing resuscitations of septic patients with liver disease.
INTRODUCTION

Elevated serum lactate has previously been shown to be a poor prognostic marker, associated with both increased morbidity and mortality in sepsis. Additionally, previous reports have demonstrated improved outcomes in patients with severe sepsis and septic shock who achieve both lactate clearance and lactate normalization. The 2012 Surviving Sepsis Campaign Guidelines recommend lactate normalization as a target of resuscitation in patients with an elevated lactate level, with a goal to achieve normalization as rapidly as possible.

Although research continues to suggest that the development of hyperlactatemia is a complex, multifactorial, and potentially patient-specific process, it is accepted that hyperlactatemia can result from either overproduction, impaired clearance, or a combination of the two. Prior research has shown that some patients with hypotension and shock develop hyperlactatemia, while others do not, suggesting a more complex process than simple hypoperfusion or hypoxia. Lactate is metabolized primarily by the liver. Though previous studies have suggested that liver dysfunction is associated with higher lactate levels in the acutely ill, the impact of liver disease (LD) on the early stages of an acute resuscitation in sepsis is not well-known. The objective of this study was to describe the effects of LD on lactate kinetics during early resuscitations in severe sepsis and septic shock.

METHODS

Study design
We conducted a secondary analysis of a completed, large, multicenter randomized control trial evaluating the non-inferiority of lactate clearance versus central oxygen saturation (ScvO2) as a marker of adequate oxygen delivery during early quantitative resuscitations in septic patients. The methodology of the trial has been previously reported. Briefly, the trial was conducted at large, urban medical centers between January 2007 and January 2009. The institutional review board at each institution approved the study, with all participants or surrogates providing written informed consent. The trial was registered on ClinicalTrials.gov, identifier NCT00372502. Abbreviated inclusion criteria were adults with suspected infection, two or more systemic inflammatory response criteria, and systolic blood pressure < 90 mmHg after a 20 mL/kg fluid challenge or an initial lactate > 4 mmol/L.

In that study, patients were randomized to 1 of 2 study groups. Each group had a structured quantitative resuscitation protocol, which has been previously described and published. The ScvO2 group (n = 150) was resuscitated by directing therapy to meet threshold values of central venous pressure, mean arterial pressure, and ScvO2. The lactate clearance group (n = 150) had similar goals in central venous pressure, mean arterial pressure, and then lactate clearance (decrease in lactate of at least 10% over at least 2 hours) instead of ScvO2. Protocols were followed until all endpoints were met or a maximum time of 6 hours elapsed.

Data analysis
Given our objective of evaluating lactate clearance, in the present study we included only patients that had an initially elevated lactate level (≥ 2 mmol/L) and a subsequent lactate level measured within six hours. We further categorized these patients by the presence of LD, as defined in two ways. In the first classification, patients were categorized by their reported past medical history (PMH) of LD, defined as either: no LD, mild LD (no Child’s score criteria), or moderate/severe LD (Child’s score > 3). As described by Vincent and colleagues, the L-SOFA score is calculated by serum bilirubin values as follows: L-SOFA 0, < 1.2 mg/dL; L-SOFA 1, 1.2 to 1.9 mg/dL; L-SOFA 2, 2.0 to 5.9 mg/dL; L-SOFA 3, 6.0 to 11.9 mg/dL; L-SOFA 4, > 12.0. The primary outcome of this study was the difference in the rate of lactate normalization (initial elevated lactate with all subsequent measurements < 2 mmol/L) between groups as defined by either PMH or L-SOFA score. The secondary outcome was the difference in relative lactate clearance ([initial lactate—subsequent lactate]/initial lactate) between groups. Fischer’s exact, Mann-Whitney U, and Kruskal-Wallis tests were used as appropriate. All statistical tests were two sided with P < 0.05 considered significant. Data were analyzed using STATA ver. 10.0 (Stata Corp., College Station, TX, USA) or StatsDirect ver. 2.7.7 (StatsDirect, Cheshire, England).

RESULTS

A total of 187 patients had an initial lactate ≥ 2 mmol/L and a subsequent lactate level measured within 6 hours and were therefore included in the present analysis, and represents the same cohort used in previous work by our group to compare the prognostic value of various measures of lactate clearance. One hundred thirteen patients were excluded from the original study for either lack of an initial lactate measurement (96 patients) or repeat lactate level within 6 hours (17 patients) (Fig. 1). When

Lactate normalization in liver disease and sepsis
compared to the included patients, the 113 excluded had no significant differences in age, sex, or race; however, the excluded patients were less likely to have a PMH of diabetes mellitus and hypertension, and had a lower total SOFA score than those patients who were included in this analysis. No significant difference in mortality was noted between the excluded and included patients. When categorized by PMH, 169 patients had no LD, 6 patients had mild LD, and 12 patients had cirrhosis. With the exception of age, no significant differences were noted in demographics, comorbid conditions, and specifically renal function, source of infection, or overall in-hospital mortality between the three groups (Table 1). Of note, while not statistically significant, baseline lactate levels were higher in the cirrhosis group overall. The median time of repeat lactate measurement for the patients with no LD, mild LD, and cirrhosis was 135 minutes (interquartile range [IQR], 112 to 205), 153 minutes (IQR, 125 to 313), and 121 minutes (IQR, 117 to 153), respectively. No statistical difference was found between the groups (P < 0.53).

For the primary outcome of lactate normalization, 63/169 (37%; 95% CI, 30% to 45%) of patients with no LD achieved lactate normalization, compared to 4/6 (67%; 95% CI, 12% to 100%) of those with mild LD, and 1/12 (8%; 95% CI, -10% to 27%) of those with cirrhosis (P < 0.03). Post hoc analysis revealed differences in the no LD group compared to cirrhosis group (37% and 8%, respectively, P = 0.04) as well as the mild LD (67%) compared with cirrhosis (8%, P = 0.01) but no differences in the no LD and mild LD groups (Fig. 2). The secondary outcome, relative lactate clearance, was likewise lower in patients with more advanced LD by PMH (37.7 vs. 40.4 vs. 21.8, P = 0.07), with significant differences between no LD (37.7%) compared with cirrhosis (21.8%, P = 0.03) (Fig. 2).

When categorized by measureable liver dysfunction by L-SOFA, 124 patients had an L-SOFA score of 0, 31 had a score of 1, and 32 had a score of 2 to 4. No significant differences were noted in patient demographics, comorbidities, and specifically renal function.

Table 1. Patient demographics and clinical characteristics grouped by past medical history of LD

|                  | No LD (n = 169) | Mild LD (n = 6) | Cirrhosis (n = 12) | P-value |
|------------------|-----------------|-----------------|--------------------|---------|
| Age (yr)         | 65 (52–75)      | 46 (41–50)      | 58 (52–65)         | 0.01    |
| Race             |                 |                 |                    |         |
| Caucasian        | 46 (56)         | 2 (33)          | 4 (33)             | 0.19    |
| Black American   | 61 (36)         | 3 (50)          | 6 (50)             |         |
| Other            | 12 (7)          | 1 (17)          | 2 (17)             |         |
| Sex              |                 |                 |                    |         |
| Male             | 89 (52)         | 4 (67)          | 9 (75)             | 0.29    |
| Female           | 80 (48)         | 2 (33)          | 3 (25)             |         |
| Disease severity |                 |                 |                    |         |
| SOFA score       | 7 (4–10)        | 3.5 (1–8)       | 6 (4.5–7.5)        | 0.08    |
| Initial lactate  | 4.3 (3–6.7)     | 3.4 (3–4.4)     | 5.6 (3.4–6.9)      | 0.36    |
| Comorbidities    |                 |                 |                    |         |
| Diabetes mellitus| 64 (38)         | 1 (17)          | 8 (67)             | 0.09    |
| Hypertension     | 103 (61)        | 3 (50)          | 10 (83)            | 0.27    |
| Congestive heart failure | 23 (14) | 0 (0) | 1 (8) | > 0.99 |
| Chronic obstructive pulmonary disease | 32 (19) | 0 (0) | 3 (25) | 0.54 |
| Peripheral vascular disease | 21 (12) | 0 (0) | 2 (17) | 0.70 |
| Source of infection |         |                 |                    |         |
| Pneumonia        | 59 (35)         | 1 (17)          | 2 (17)             | 0.38    |
| Urinary tract infection/ pyelonephritis | 47 (28) | 0 (0) | 2 (17) | 0.25 |
| Intraabdominal   | 28 (17)         | 2 (33)          | 4 (33)             | 0.18    |
| Biliary          | 5 (3)           | 0 (0)           | 2 (17)             | 0.08    |
| Interventions    |                 |                 |                    |         |
| Total fluids in ED (L) | 4 (3–5.4) | 2.6 (2–7) | 3.7 (2.1–4.4) | 0.26 |
| Vasopressor use  | 110 (65)        | 3 (50)          | 6 (50)             | 0.44    |
| Mortality        | 40 (24)         | 0 (0)           | 4 (33)             | 0.34    |

Values are presented as n (%) unless otherwise indicated.
LD, liver disease; SOFA, sequential organ failure assessment; ED, emergency department.
*Median (interquartile range). *Disease severity scores calculated at time of enrollment.

Fig. 1. Flowchart of patient inclusion.

Fig. 2. Achievement of lactate normalization and rate of lactate clearance when classified by past medical history of liver disease (LD). *P < 0.05.
**Table 2.** Patient demographics and clinical characteristics grouped by liver SOFA score

| Liver SOFA 0 | Liver SOFA 1 | Liver SOFA 2–4 | P-value |
|--------------|--------------|----------------|---------|
| (n = 124)    | (n = 31)     | (n = 32)       |         |
| Age (yr)<sup>a</sup> | 64 (50–76) | 58 (52–68) | 64 (54–71) | 0.53 |
| Race         |              |                |         |
| Caucasian    | 68 (55)      | 15 (48)       | 18 (56) | 0.55 |
| Black American | 46 (37)   | 12 (39)       | 38 (38) |         |
| Other        | 10 (8)       | 4 (13)        | 2 (6)  |         |
| Sex          |              |                |         |
| Male         | 67 (54)      | 17 (55)       | 18 (56) | 0.97 |
| Female       | 57 (46)      | 14 (45)       | 14 (44) |         |
| Disease severity<sup>a,b</sup> |              |                |         |
| SOFA score–total | 6 (4–9) | 8 (4–10) | 8 (6.5–12) | <0.01 |
| Initial lactate | 4.1 (2–6) | 4.3 (2.3–6.3) | 6.4 (3.5–7.8) | 0.03 |
| Comorbidities |              |                |         |
| Diabetes mellitus | 54 (44) | 8 (26)       | 11 (34) | 0.17 |
| Hypertension  | 78 (63)      | 17 (55)       | 21 (66) | 0.64 |
| Congestive heart failure | 16 (13) | 4 (13) | 4 (13) | >0.99 |
| Chronic obstructive pulmonary disease | 22 (18) | 8 (26) | 5 (16) | 0.51 |
| Peripheral vascular disease | 14 (11) | 3 (10) | 6 (19) | 0.43 |
| Source of infection |              |                |         |
| Pneumonia | 48 (39)      | 9 (29)        | 5 (16) | 0.04 |
| Urinary tract infection/ pyelonephritis | 32 (26) | 10 (32) | 7 (22) | 0.64 |
| Intraabdominal | 17 (14) | 6 (19) | 11 (34) | 0.03 |
| Biliary | 0 (0)        | 1 (3)         | 6 (19) | <0.01 |
| Interventions |              |                |         |
| Total fluids in ED (L)<sup>b</sup> | 4 (3–5.6) | 4 (2.2–5) | 3 (2.4–5) | 0.14 |
| Vasopressor use | 79 (64) | 19 (61) | 21 (66) | 0.94 |
| Mortality | 27 (22) | 6 (23) | 10 (31) | 0.53 |

Values are presented as n (%) unless otherwise indicated.

<sup>a</sup>Median (interquartile range).<sup>b</sup>Disease severity scores calculated at time of enrollment.

...mission, or overall in-hospital mortality between the groups; however, significant differences were noted between the groups in total SOFA score and initial lactate level, as well as in the source of infection (Table 2). Of note, while not statistically significant, baseline lactate levels were higher in the L-SOFA 2–4 groups overall. The median time of repeat lactate measurement for the L-SOFA 0, L-SOFA 1, and L-SOFA 2–4 was 134 minutes (IQR, 114 to 216), 148 minutes (IQR, 123 to 205), and 126 minutes (IQR, 114 to 153), respectively. No statistical difference was found between the groups (P<0.35).

For the primary outcome, 59/124 (47%; 95% CI, 37% to 56%) patients with a L-SOFA of 0 achieved lactate normalization, compared to 6/31 (19%; 95% CI, 9% to 34%) with L-SOFA of 1, and 3/32 (9%; 95% CI, −1% to 20%) with a L-SOFA of 2–4 (P<0.01).

**DISCUSSION**

In this analysis, we sought to evaluate the effect of LD on lactate clearance during the early phase of quantitative resuscitations in severe sepsis and septic shock. Our results indicate that liver dysfunction, defined either by preexisting PMH or by L-SOFA score, are associated with differences in both lactate clearance and lactate normalization. These results highlight a patient population in whom delayed lactate clearance, and thus prolonged hyperlactatemia may occur, and a clinical scenario where the resolution of hyperlactatemia may be more difficult to achieve.

For this analysis, we chose to evaluate the presence of LD in two distinct ways, by reported PMH of LD and by measurable liver dysfunction using the liver component of their SOFA score on presentation. Using both of these approaches, we were able to capture patients who historically had known chronic disease, but potentially no laboratory changes, and patients who may or may not have known of underlying liver dysfunction, but acutely had...
measurable objective evidence of liver dysfunction on presentation. Using two approaches, we were able to more fully assess the impact of LD and dysfunction on lactate kinetics, using easily attainable, clinically relevant definitions. The fact that outcomes were similar regardless of the method of categorization supports the conclusion that the observed associations are likely important and clinically relevant.

While the difference in lactate normalization was significant in both the group defined by PMH and L-SOFA, a more obvious association was noted when using L-SOFA score. While this may indicate that objective evidence of liver dysfunction by laboratory testing may be more important than PMH in predicting impact on lactate clearance, this may also simply be a reflection of the fact that patients were more evenly distributed across LD categories as defined by SOFA score as compared to PMH. This is particularly evident in the case of “mild” groups. Using the L-SOFA definition (liver SOFA 1), there were observable effects on lactate normalization, but, the historical presence of “mild LD” did not appear to impact lactate normalization or the rate of lactate clearance in this study, though this may have been limited by the small sample size (6 patients) and lower comorbidity burden (Table 1) within this subgroup. The presence of cirrhosis by history, however, had marked effects on both lactate normalization and clearance. These results suggest that acute liver dysfunction on presentation, assessed using the L-SOFA, or a PMH of cirrhosis may impact the early resuscitation goals in severe sepsis and septic shock. Despite the notable effects of LD on lactate normalization and rate of clearance, this did not translate into a statistically significant difference in mortality between the groups, although the highest mortality rates were observed in the patients with either cirrhosis or L-SOFA 2–4. However, given that mortality was not a primary outcome in our study and noting the relatively small number of patients with severe LD, these observations are merely hypothesis generating.

Our results are similar to previous studies evaluating lactate levels in patients with LD. De Jonghe et al.15 noted an elevated lactate level in patients with evidence of early hepatic dysfunction and circulatory failure. While they found hepatic dysfunction was associated with an elevated serum lactate, they did not note a difference in mortality. However, contrasting with our study, their study evaluated intensive care unit patients with undifferentiated circulatory failure and was not specific to severe sepsis or septic shock, nor did it assess lactate clearance.19 Our study extends their findings by additionally evaluating lactate normalization and clearance during acute, quantitative resuscitations in the initial resuscitation period of patients with severe sepsis and septic shock. In another study, Dugas et al.15 evaluated vasopres-

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Mikkelsen ME, Mittiales AN, Gaiesski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009;37:1670–7.
2. Puskarich MA, Klime JA, Summers RL, Jones AE. Prognostic value of incremental lactate elevations in emergency department patients with suspected infection. Acad Emerg Med 2012;19:983-5.
3. Song YH, Shin TG, Kang MJ, et al. Predicting factors associated with clinical deterioration of sepsis patients with intermediate levels of serum lactate. Shock 2012;38:249-54.
4. Puskarich MA, Trzeciak S, Shapiro NI, et al. Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. Acad Emerg Med 2012;19:252-8.
5. Park JH, Lee J, Park YS, et al. Prognostic value of central venous oxygen saturation and blood lactate levels measured simultaneously in the same patients with severe systemic inflammatory response syndrome and severe sepsis. Lung 2014;192:435-40.
6. Zhang Z, Xu X. Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2014;42:2118-25.
7. Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-42.
8. Puskarich MA, Trzeciak S, Shapiro NI, et al. Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock. Chest 2013;143:1548-53.
9. Jansen TC, van Bommel J, Schoonderbeek FJ, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010;182:752-61.
10. Arnold RC, Shapiro NI, Jones AE, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock 2009;32:35-9.
11. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
12. Hernandez G, Castro R, Romero C, et al. Persistent sepsis-induced hypotension without hyperlactatemia: is it really septic shock? J Crit Care 2011;26:435.e9-14.
13. Hernandez G, Bruhn A, Castro R, et al. Persistent sepsis-induced hypotension without hyperlactatemia: a distinct clinical and physiological profile within the spectrum of septic shock. Crit Care Res Pract 2012;2012:536852.
14. Sterling SA, Puskarich MA, Shapiro NI, et al. Characteristics and outcomes of patients with vasoplegic versus tissue dysoxic septic shock. Shock 2013;40:11-4.
15. Dugas AF, Mackenhauer J, Salciccioli JD, Cocchi MN, Gautam S, Donnino MW. Prevalence and characteristics of nonlactate and lactate expressors in septic shock. J Crit Care 2012;27:344-50.
16. Connor H, Woods HF, Ledingham JG, Murray JD. A model of L(+)-lactate metabolism in normal man. Ann Nutr Metab 1982;26:254-63.
17. Rowell LB, Kraning KK 2nd, Evans TO, Kennedy JW, Blackmon JR, Kusumi F. Splanchnic removal of lactate and pyruvate during prolonged exercise in man. J Appl Physiol 1966;21:1773-83.
18. Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, Gerich JE. Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans. Am J Physiol 1990;259(5 Pt 1):E677-84.
19. De Jonghe B, Cheval C, Misset B, et al. Relationship between blood lactate and early hepatic dysfunction in acute circulatory failure. J Crit Care 1999;14:7-11.
20. Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base disturbances in critically ill patients with cirrhosis. Liver Int 2007;27:901-9.
21. Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010;303:739-46.
22. Child CG, Turcotte JG. The liver and portal hypertension. Philadelphia, PA: Saunders; 1964.
23. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
24. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:738-46.
25. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998;26:1793-800.